A modular, phase 2 trial by Ana Aparicio, MD, and colleagues sought to determine the efficacy and safety of combining androgen signaling inhibitors for patients with metastatic castration-resistant prostate cancer (mCRPC). The combination of abiraterone acetate, prednisone, and apalutamide (AAPA) is commonly used as a treatment for mCRPC due to its potential to improve outcomes and delay resistance. The randomized trial added ipilimumab to the combination to determine its efficacy in 192 eligible patients. ...
CRPC
Advertisement
Latest News
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
The study’s primary end points were the incidence of all-grade or grade 3 and higher cardiovascular events.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Enhancing Genetic Testing Rates in Metastatic Prostate Cancer: Trends, Challenges, and Opportunities
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC. Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
